Key result
A half-dose combination of trandolapril and valsartan significantly lowered MMP-9 levels and suppressed left ventricular remodeling more effectively than trandolapril alone at 12 months in patients with acute myocardial infarction post-PCI.
Why the study?
Does a combination of half-dose trandolapril and valsartan improve left ventricular remodeling and reduce MMP-9 levels compared to regular dose monotherapy in post-AMI patients after primary PCI?
RCT (n=65)
Open-label
Minimization method
Yes
Does a combination of half-dose trandolapril and valsartan improve left ventricular remodeling and reduce MMP-9 levels compared to regular dose monotherapy in post-AMI patients after primary PCI?
A half-dose combination of trandolapril and valsartan may suppress left ventricular remodeling and MMP-9 levels more effectively than trandolapril alone in post-AMI patients after primary PCI.
Answers are grounded in this paper and cite their sources.
Supports half-dose trandolapril-valsartan over monotherapy post-AMI; extends remodeling evidence with MMP-9 suppression.
BACKGROUND: Inhibition of the renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) can suppress left ventricular (LV) remodeling after acute myocardial infarction (AMI), possibly through the modifications of matrix metalloproteinase (MMP)-9. Whether LV remodeling is suppressed in association with MMP-9 suppression in post-AMI/-percutaneous coronary intervention (PCI) patients treated with ACE inhibitor and/or ARB was examined. The presence of any differences in LV remodeling and MMP-9 levels across the groups was also investigated. METHODS AND RESULTS: Sixty-five patients were initiated into each of 3 treatments; trandolapril, valsartan or a combination of both (half-dose-trandolapril plus half-dose-valsartan). Changes in MMP-9, LV end-diastolic and end-systolic volume index (LVEDVI and LVESVI) after 12 months were assessed. Overall, MMP-9 significantly decreased, although neither LVEDVI nor LVESVI increased significantly. DeltaMMP-9 was significantly correlated with DeltaLVEDVI (r=0.36) or DeltaLVESVI (r=0.39). In comparison, across groups, it was found that MMP-9, LVEDVI and LVESVI at 12 months were significantly lower in the combination therapy group than in the trandolapril group. There were no significant differences between the valsartan group and combination therapy group, or between the valsartan group and the trandolapril group. CONCLUSIONS: LV remodeling might be suppressed in association with MMP-9 suppression in AMI patients treated with PCI and regular dose or half-dose-combination of RAS inhibitors. Furthermore, a half-dose-combination might suppress LV remodeling more effectively than trandolapril alone.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2010) conducted an RCT in Acute Myocardial Infarction (n=65). Combination of trandolapril and valsartan vs. Trandolapril alone (1-2 mg/day) or Valsartan alone (80-160 mg/day) was evaluated on Left ventricular remodeling (LVEDVI and LVESVI) and MMP-9 levels at 12 months. A half-dose combination of trandolapril and valsartan significantly lowered MMP-9 levels and suppressed left ventricular remodeling more effectively than trandolapril alone at 12 months in patients with acute myocardial infarction post-PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: